News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GTX Corp to Present Scientific Poster Presentations on Enobosarm to Prevent and Treat Muscle Wasting in Cancer Patients



10/8/2012 9:50:20 AM

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) announced today there will be two scientific poster presentations on the effects of enobosarm, a selective androgen receptor modulator (SARM), on improving physical function and quality of life in middle aged and elderly cancer patients. The posters will be displayed on October 26th and 27th, 2012, at the 12th Meeting of the International Society of Geriatric Oncology to be held at the Manchester Central Convention Centre in Manchester, United Kingdom. Ryan P. Taylor, PhD, GTx’s Associate Director of Medical Affairs, will present data from the company’s Phase IIb clinical study of enobosarm, providing evidence that enobosarm may play an important role in the management of cancer patients with muscle wasting by improving physical function and quality of life, regardless of baseline weight loss or age.

Read at BioSpace.com


comments powered by Disqus
GTX Corp
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES